Reviva RVPH 深 沪
等待开盘 06-26 09:30:00 美东时间
0.3521
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.3521
- 总市值 5328.43493
- 52周最高 3.52
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.17
- 委 比 0.00%
- 总股本 1.51万
- 历史最高 15.10
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.17
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Intel's Apple-Driven Surge Gets A Harsh Verdict: 'It's Becoming A Meme Stock'
Intel stock hits 52-week high on Apple foundry rumors, but Wall Street analysts are sharply divided on whether massive rally is justified.
06-22 17:41
OSR Health Changes Name From OSR Holdings; Continues Trading Under Existing Ticker
Effective June 11, 2026, OSR Health, Inc. (formerly OSR Holdings, Inc.) (the "Company") changed its corporate name from "OSR Holdings, Inc." to "OSR Health, Inc." The name change was effected through the filing of a
06-18 00:33
Reviva Pharmaceuticals To Be Delisted From Nasdaq On May 14
As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the "Company") was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") to maintain
05-13 20:28
Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces Bankruptcy
Major M&A deals include: Amazon's $11.6 billion acquisition of Globalstar, OpenAI buys Hiro Finance, and AIP acquires Avanos Medical.
04-18 02:33
What's Behind The Drop In Reviva Pharmaceuticals Stock?
Reviva Pharmaceuticals shares are tumbling Thursday after pricing a $10 million public offering of over 6 million shares at $1.50 per share.
03-20 00:49
Gold Tumbles Over 6%; Accenture Earnings Top Views
U.S. stocks traded lower midway through trading, with the Nasdaq Composite fall...
03-20 00:01
US Stocks Mixed; GDP Growth Tops Expectations
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around...
2025-12-23 23:01
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals' Phase 3 RECOVER OLE study of brilaroxazine for schizophrenia demonstrates sustained broad-spectrum efficacy over 1 year, with low adverse events and a 35% discontinuation rate. Positive results across symptom domains, enhanced by improved neuroinflammatory markers, highlight its potential to address unmet needs in schizophrenia treatment.
2025-06-02 11:00
EF Hutton Initiates Coverage On Reviva Pharmaceuticals with Buy Rating, Announces Price Target of $15
EF Hutton analyst Jason Kolbert initiates coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy rating and announces Price Target of $15.
2024-09-23 20:36
